Quote this publication Share Print

ENBREL (etanercept), anti-TNF

Opinions on drugs - Posted on Jul 06 2016

Reason for request

Extension of Inclusion

Second-line treatments in juvenileidiopathic arthritis (JIA) in case of insufficient response or intolerance to methotrexate.

  • Two anti-TNFs, HUMIRA and ENBREL, which have Marketing Authorisation as a first-line treatment for the active polyarticular form of JIA now have Marketing Authorisation in other forms of the disease:
    • the enthesitis-related form, from 6 years of age for HUMIRA and from 12 years of age for ENBREL.
    • psoriatic arthritis from 6 years of age and extended oligoarthritis from 2 years of age, for ENBREL only.
  • These are second-line treatments, prescribed in case of insufficient response or intolerance to methotrexate, reference long-term first line treatment.

Clinical Benefit



Clinical Added Value

no clinical added value


Therapeutic use


Contact Us

Évaluation des médicaments